Clee Medical secures financing to advance real-time brain imaging platform

Geneva-based Clee Medical has raised Seed funding to accelerate clinical validation of its Neuro Access imaging technology for minimally invasive neurosurgery.

Geneva-based neurotechnology start-up Clee Medical has closed a Seed financing round to accelerate the development and clinical validation of its Neuro Access platform, a minimally invasive imaging technology designed for neurosurgery.

The company is developing an ultra-high-resolution, real-time imaging system intended to improve visualization of brain anatomy during stereotactic procedures. In current practice, neurosurgeons rely heavily on pre-operative imaging, while intraoperative conditions can shift dynamically. Clee Medical aims to bridge this gap by enabling real-time insight into critical brain structures during surgery.

The Seed financing will support the expansion of development and clinical programs, including preparations for a first-in-human clinical study. The round was led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank, Kickfund, FONGIT, Venture Kick and continued backing from Wyss Geneva.

From translational research to clinical adoption in precision neurosurgery

Clee Medical’s technology builds on years of translational research and targets applications in functional neurosurgery and neuro-oncology, where millimeter-level precision is essential. By enhancing intraoperative visibility, the platform is designed to support safer procedures and expand the capabilities of minimally invasive brain surgery.

Founded by Matt Lapinski and Abed Hammoud, the company combines experience in scaling Class III medical devices with expertise in precision surgical navigation systems. With support from a European investor syndicate, Clee Medical is advancing from preclinical development toward early clinical adoption, reinforcing Geneva’s position in high-value neurotechnology innovation.